2021 Netherlands Tumor Marker Market Assessment--Oncogenes, Bio Markers, GFs, CSFs, Hormones, Stains, Lymphokines--Competitive Shares and Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

This new report from LeadingMarketResearch.com provides a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines emerging trends in the cancer diagnostics market; reviews current and emerging tests; analyzes potential applications of innovative technologies; forecasts volume and sales for major cancer diagnostics tests; profiles leading market players and potential entrants; and suggests alternative market expansion strategies for suppliers.

The report is available by section, and can be customized to specific information needs and budget.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

Business Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal during the next five years. - Design criteria for new products. - Alternative market penetration strategies. - Potential market entry barriers and risks.

Cancer Diagnostic Tests Analyzed in the Report--over 200 current and emerging assays, including Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines and Immunohistochemical Stains, such as:

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Instrumentation Review

- Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

Technology Review

- Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.

- Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

- Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Assessments

- Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

Contains 535 pages and 70 tables

This new report from LeadingMarketResearch.com provides a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines emerging trends in the cancer diagnostics market; reviews current and emerging tests; analyzes potential applications of innovative technologies; forecasts volume and sales for major cancer diagnostics tests; profiles leading market players and potential entrants; and suggests alternative market expansion strategies for suppliers.

I. Introduction
II. Market Overview
III. Major Product Development Opportunities
IV. Design Criteria for Decentralized Testing Products
V. Alternative Market Penetration Strategies
VI. Potential Market Entry Barriers and Risks
VII. Major Current and Emerging Cancer Diagnostic Tests
1. Introduction
2. Cancer Diagnostic Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Cancer Diagnostics
27. Oncogenes
- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src and others
28. Polypeptide Growth Factors
- Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR
- Nerve Growth Factor (NGF)
- Epidermal Growth Factor (EGF)
- Ornithine Decarboxylase
- Transferrin
- Transforming Growth Factor-Alpha
29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
- Alpha-Interferon
- B Cell Growth Factors
- B Cell Growth Factor (BCGF)
- Gamma-Interferon
- Interleukin-1 (IL-1)
- Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Cancer Diagnostics
- N-Acetylglucosamine
- ctin
- Alpha-Actin
- Antineuronal Antibodies
- 7B2
- B72.3
- Bax
- BCD-F9
- BLCA-4
- Blood Group Antigens A,B,H
- CA 50
- CA 72-4/TAG-72
- CA 195
- CA-242
- CA-549
- CAM 26
- CAR-3
- Cathepsin-D
- Chromogranin A and B
- Cluster 1 Antigen
- Cluster-5/5A Antigen
- CTA
- CU18
- DR-70
- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- Feulgen Hydrolysis
- Fibronectin
- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- Her-2
- Human Carcinoma Antigen
- HPA
- HSP27
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
- KA 93
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma 552
- MABDF3
- MAG
- ME1
- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor 1
- Myosin
- NEA-130
- NMP22
- OA-519
- Opiod Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Placental Lactogen
- PR92
- Proliferative Index, Ki-67
- Px
- RB Inactivation/Deletion
- Ret
- SCCL 175
- Selectin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somatostatin
- TA-90
- TABA
- Tachykinin
- TAG 12
- TPS
- Troponin
- Tubulin
- VCAM
- VEGF
- Villen and others
VIII. Instrumentation Review and Market Needs
IX. Current and Emerging Technologies
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
3. Molecular Diagnostics
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
X. Market Size, Test Volume and Sales Forecasts
XI. Competitive Profiles
The report provides strategic assessments of over 30 leading cancer diagnostics market players and
start-up companies with innovative technologies and products, including:
- Abbott
- Affymetrix
- Beckman Coulter/Danaher
- Becton Dickinson
- bioMerieux
- Bio-Rad
- Cepheid
- DiaSorin
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Fujirebio
- Grifols
- Hologic
- Leica Biosystems
- Ortho-Clinical Diagnostics
- PerkinElmer
- Qiagen
- Roche
- Siemens Healthineers
- Takara Bio
- Thermo Fisher
- Wako and others.


List Of Tables

Cancer Diagnostic Test Volume and Sales Forecasts
Cancer Diagnostic Volume Forecast by Test
Cancer Diagnostics Sales Forecast by Test
Cancer Diagnostic Classification
Major Companies Developing or Marketing ACTH Tests
Major Companies Developing or Marketing AFP Tests
Major Companies Developing or Marketing Beta-2 Microglobulin Tests
Major Companies Developing or Marketing CA 15-3/27.29 Tests
Major Companies Developing or Marketing CA 19-9 Tests
Major Companies Developing or Marketing CA 125 Tests
Major Companies Developing or Marketing Calcitonin Tests
Major Companies Developing or Marketing CEA Tests
Major Companies Developing or Marketing Estrogen Receptor Tests
Major Companies Developing or Marketing Progesterone Receptor Tests
Major Companies Developing or Marketing Ferritin Tests
Major Companies Developing or Marketing Gastrin Tests
Major Companies Developing or Marketing HCG Tests
Major Companies Developing or Marketing Insulin Tests
Major Companies Developing or Marketing NSE Tests
Major Companies Developing or Marketing Occult Blood Tests
Major Companies Developing or Marketing PAP Smear/HPV Tests
Major Companies Developing or Marketing PAP Tests
Major Companies Developing or Marketing PSA Tests
Major Companies Developing or Marketing Lymphocyte Sub-classification Tests
Biochemical Markers Potential Applications in Cancer Diagnosis
Oncogenes Potential Applications in Cancer Diagnosis
Major Companies Developing or Marketing Oncogene Tests
Growth Factors Potential Applications in Cancer Diagnosis
Colony Stimulating Factors Potential Applications in Cancer Diagnosis
Lymphokines Potential Applications in Cancer Diagnosis
Immunohistochemical Stains Potential Applications in Cancer Diagnosis


Global Neuromodulation Devices Market Outlook 2021: Global Opportunity and Demand Analysis, Market Forecast to 2030

The neuromodulation devices market is anticipated to grow at a CAGR of 6.5% over the forecast period of 20202028. According to a study published by Insure Insights on the neuromodulation

USD 3950 View Report

Global Neuromarketing Solutions Market Outlook 2021: Global Opportunity and Demand Analysis, Market Forecast, 2022-2030

The Global Neuromarketing Solutions market is anticipated to rise at a value CAGR of 9.65% over 20202028. According to a study published by Insure Insights on the Global Neuromarketing Solutions

USD 3950 View Report

Netherlands Tumor Markers Diagnostic Testing Market Assessment

This new report from LeadingMarketResearch.com provides a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines emerging trends

USD  1850 View Report

 Netherlands Tumor Markers Testing Market High Growth Opportunities for Cancer Diagnostic Tests and Analyzers  

This new report from provides a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years.The report is available by section,

USD 2500 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available